Chronic hepatitis B virus (HBV) infection and HBV-related hepatitis in children remains an unmet medical need, as current treatments are only partially effective, and only in a limited number of affected children. So-called "immunotolerant" children have not shown increased serological responses to available treatments. In cases involving more active disease, serological response has only been obtained in approximately one-third of patients when using interferon, while other cases exhibited virological response solely under continuous treatment with nucleoside analogs. Guidelines have recently been established to aid pediatricians in effectively managing this condition. With the available medications, no treatment is so far indicated for immunotolerant children, but only for cases presenting increased alanine aminotransferase levels to over 1.5-2 times the upper limit of normal for over 6 months, and without spontaneous HB envelope antigen to antibody seroconversion. The therapeutic arsenal approved by the Food and Drugs Administration and European Medicines Agency for children remains limited because of the lack of large-scale clinical trials validating treatments already approved for the adult population. Yet, the recent discovery of a specific HBV-cell surface receptor, NTCP, allows for new treatment perspectives regarding the future.
Introduction
Chronic hepatitis B (CHB) in children remains a major clinical issue for pediatricians, because there are still over 360 million hepatitis B virus (HBV)-infected subjects worldwide, including numerous children. [1] [2] [3] Even though large vaccination campaigns have succeeded in reducing disease prevalence in several countries, the incidence is still high at a worldwide level, thus requiring immediate attention. The transmission route varies depending on geographical region. 2, 4, 5 In highly endemic countries, vertical transmission from mother to child is predominant, whereas in low-endemic countries, the disease primarily involves adults infected by sexual or parenteral transmission. Significant success has been achieved in limiting vertical transmission by administering vaccines and hepatitis B immunoglobulins to newborns of mothers carrying HB surface antigens (HBsAg) within 24 h of birth (World Health Organization recommendations 6 ). Although HBV-related chronic infection has proven rather benign during early childhood and adolescence, pediatric CHB remains difficult to manage. Even if most CHB subjects are asymptomatic during childhood, these chronic carriers are at risk of developing cirrhosis or hepatocellular carcinoma (HCC) later in life, with 3-5% usually developing cirrhosis, while 0.01-0.03% will develop HCC.
2 Several treatment strategies have been developed for adults, yet extrapolating the clinical results to children is not feasible. And CHB management in children is hampered by the chronic delay in licensing new drugs, owing to the lack of appropriate clinical trials.
Chronic hepatitis B is defined as the presence of HBsAg over a period exceeding 6 months, 2 with three distinct phases described in children. 2, 7 The first is the immune-tolerant phase, characterized by positive HB envelope antigen (HBeAg), high HBV-DNA levels, yet normal alanine aminotransferase (ALT). This phase can last a long time (10-30 years), with liver damage typically limited. The second is the immune-active phase comprising ALT level increases and active inflammation in the liver. The third is the inactive carrier state, where HBeAg becomes negative, ALT levels normalize, and HBV-DNA rates decrease or disappear. In this latter situation, persistent elevated ALT levels and HBV-DNA > 2000 IU may imply a possible HBeAg-negative CHB, involving a pre-core mutant virus. For low-income and middle-income countries, where the number of people infected remains high, the cost of the vaccine is still an unresolved issue. Another challenge to overcome is the economic hurdles for improving disease prevention at a worldwide level in an effort to reduce the disease's global burden. Whereas the loss of HBsAg along with the development of hepatitis B surface antibody (HBsAb) is considered the ultimate treatment goal, this is rarely achieved with current treatment modalities. When reading the next sections, please keep in mind that loss of antigen E (HBeAg) along with the development of hepatitis B envelope antibody (HBeAb) is meant when referring to seroconversion.
When should we treat chronic hepatitis B in children?. The ultimate goal of treatment is to improve survival and limit disease progression towards cirrhosis and HCC. 8 The guidelines formulated by a panel of experts (European Society for Pediatric Gastroenterology, Hepatology, and Nutrition [ESPGHAN]) recommend monitoring chronic HBV infection every 6 months, including ALT levels, HBeAg rates, and antibody (HBeAb) status. 2 It has now been clearly established that no treatment should be proposed to immunotolerant patients because of the risk of them developing HBV resistance. When ALT levels increase, a further 6-month observation is recommended before treatment is initiated. ALT levels may, in fact, be increased as a result of other infections or because of spontaneous HBeAg seroconversion, rendering treatment unnecessary. 2, 4, 9 Recommendations further state that treatment should be initiated if a patient presents ALT levels over 1.5-2.0 times the laboratory upper limit of normal, or exceeding 60 IU/L. In addition, serum HBV-DNA rates should be closely monitored, with a cutoff value of 20 000 IU/mL currently agreed upon. The decision to initiate treatment can be facilitated by using a treatment algorithm provided by ESPGHAN. This algorithm was generated based on either the ESPGHAN experts' personal experience or findings published before 2012. 2 How should we treat children with chronic hepatitis B?. The therapeutic arsenal approved by the Food and Drug Administration (FDA) for children comprises five drugs: interferon-α, lamivudine, entecavir, adefovir, and tenofovir. The European Medicines Agency (EMA) has approved all five for treating CHB in adults, with only tenofovir and entecavir approved for pediatric populations. Interferon. In 1998, we published the results of a large clinical trial administering interferon (IFN)-α to HBV-infected children. 10 The combined serological and virological response after 24 weeks of therapy was 26% in interferon-treated children versus 11% in controls. In addition, HBsAg loss was documented in 10% of treated patients versus 1.2% in controls. One major IFN disadvantage is its short half-live, requiring multiple injections per week. In adults, pegylated interferon (PEG-IFN) has been shown to be effective in just one injection per week.
11 PEG-IFN has not yet been approved for CHB in children, although clinical trials are currently underway, with efficacy and safety results expected in the next years.
Lamivudine. Lamivudine is a nucleoside analog reverse transcriptase inhibitor. In 2002, we published the results of a large international clinical trial on lamivudine in HBV children, where 288 children were randomized according to a 2:1 ratio (lamivudine vs. placebo). 12 Following 52 weeks of treatment, HBV-DNA and HBeAg clearance in treated children was 23% versus 13% in the placebo group (ns). The median time to ALT normalization was 24 weeks for the lamivudine-treated group. Lamivudine was well tolerated, with similar adverse events reported in both groups. Whereas once-daily oral lamivudine administration appears to be a highly attractive modality, it must unfortunately be noted that this antiviral has meanwhile been associated with a high risk of virus mutation and resistance. YMDD-variant HBV was thus identified in 19% of patients receiving lamivudine for 52 weeks. It is importance to notice that in this trial, seroconversion was much higher in children with elevated transaminases.
Entecavir. Entecavir is a guanosine nucleoside analog active against HBV polymerase. A study evaluating entecavir was performed involving 180 nucleoside-treatment-naïve children and adolescents aged 2-18 years presenting with HBeAg-positive CHB infection, compensated liver disease, and elevated ALT levels. The subjects were randomized (2:1) to receive blinded treatment with either entecavir, at 0.015 mg/kg up to 0.5 mg/day (n = 120), or placebo (n = 60). The primary efficacy parameter was a composite endpoint including HBeAg seroconversion and serum HBV-DNA < 50 IU/mL (approximately 300 copies/mL) at Week 48. This endpoint was met by 24% (20/82) of the entecavir-treated subjects versus 2% (1/41) of placebo-treated ones. At Week 48, 46% (38/82) of the entecavir-treated but only 2% (1/41) of placebo-treated subjects achieved HBV-DNA < 50 IU/mL. ALT normalization occurred in 67% (55/82) of the entecavir-treated and 22% (9/41) of placebo-treated subjects, while 24% (20/82) of the entecavir-treated and 12% (5/41) of placebo-treated subjects exhibited HBeAg seroconversion.
Adefovir dipivoxil. Adefovir dipivoxil is a nucleotide analog, approved only for children over 12 years old because of the lack of efficacy observed in younger children. In 2008, the results of a large study involving 173 CHB children were published, 13 with children been given either adefovir dipivoxil or placebo. Serum HBV-DNA levels were below 1000 copies/mL and ALT levels normal after 48 weeks of treatment for 23% of the adefovir-treated subjects (compared with 0% in the placebo-control ones). However, no significant difference was observed for younger children under 12 years of age. Adefovir dipivoxil was well tolerated, and all documented adverse events were mild, with no renal toxicity. In 2012, the long-term follow-up data for these children was reported.
14 Adefovir dipivoxil had been administered in an open-label manner to 162 children, originating from either the adefovir-treated or placebo group. Adefovir was shown to be well tolerated over the entire study duration (5 years). However, viremia persistence after 24 weeks of adefovir treatment was observed in 61/162 patients. For the other subjects receiving adefovir with or without lamivudine, continued HBV-DNA suppression was reported, as was ALT level normalization. HBeAg seroconversion was documented in 55 children, for a mean duration of 762 (+/À371.2) days in the adefovir dipivoxil and 643 (+/À291.5) days in the placebo-adefovir group.
Tenofovir. In 2012, a Phase 3 clinical trial was published, evaluating tenofovir administered for 72 weeks versus placebo in adolescents aged 12 to < 18 years old. 15 An open-label extension study was also proposed to the participants for a further 120 weeks. Virological response (HBV-DNA < 400 copies/mL) was achieved in 89% of patients, compared with 0% of those treated with placebo (P < 0.001). ALT normalization occurred in 74% and 31% of patients treated with tenofovir and placebo, respectively (P < 0.001). HBeAg clearance rates, however, did not differ between both groups. Tenofovir proved safe and no patients developed resistance.
Telbivudine. This drug has not yet been approved in either the USA or Europe for use in children. Telbivudine is an enantiomer of nucleoside thymidine. Phase 1 study results were published in 2013 16 with telbivudine given to children aged 2 to 18 years old. Telbivudine was well tolerated, and all adverse events were mild. The administered doses were 600 mg/day for adolescents (> 12-18 years) and 15 or 25 mg/kg of body weight (up to a maximum of 600 mg) for children aged 2 to 12 years. Given that the plasma exposure was similar to that in adults having received 600 mg of telbivudine per day, the recommended pediatric dose was fixed at 20 mg/kg per day (up to a maximum of 600 mg/day). Further, telbivudine efficacy and safety data are currently collected in ongoing clinical trials.
Challenges and perspectives. Although authorized drugs are available at present for treating chronic HBV patients, the wide use of these drugs for children remains controversial. Not all drugs approved by the FDA for use in children have been approved by the EMA, possibly because of a lack of consensus regarding either the benefits to be sought or the endpoints to be considered when treating children.
According to the ESPGHAN guidelines, decision to initiate treatment is primarily based on ALT levels as indirect marker of ongoing liver injury. Antiviral treatment should be considered for children with elevated ALT levels for at least 6 months, in order to avoid treating patients undergoing spontaneous HBeAg seronconversion. Because the upper limit of normal (ULN) for ALT in children has not been clearly established, ESPGHAN guidelines recommend that patients be considered for antiviral therapy if ALT levels exceed either 1.5-2.0 times the laboratory ULN or 60 IU/L, as acknowledged in the manuscript.
In the presence of high ALT levels, assessing serum HBV-DNA is required, with high HBV-DNA values warranting antiviral therapy, whereas low levels call for further investigations to exclude other causes for liver injury. In addition, other factors must be considered prior to initiating therapy: liver histology, family HCC history, coexisting liver diseases, and prior treatments.
Recent research has deepened our understanding of the HBV cycle, leading to the identification of a protein, human sodium taurocholate cotransporting peptide (NTCP), a functional receptor for HBV and HDV. This protein directly interacts with the preS1 peptide of the HBV-L envelope protein, which plays a crucial role in HBV and HD virus (HDV) infection. 17 Myrcludex B, the leading substance of the first-entry inhibitor for HBV/HDV infection, appears to be a very attractive option because of its exclusive targeting of susceptible cells. The peptide is currently in Phase 1 and 2 clinical trials. 18 In 2013, Volz et al. demonstrated that Myrcludex B efficiently prevented viral spreading from the initially infected human hepatocytes, reporting a lack of increase in viremia, antigen levels, and HBcAg-positive human hepatocyte quantities, measured 6 weeks post-treatment. 19 Very recently, using the Slc10a1-knockout model (Slc10a1 encodes NTCP), Slijepcevic et al. reported that NTCP was essential for Myrcludex B binding in vivo, with a total lack of liver association in Slc10a1À/Àmice, indicating that the association with NTCP mediates the liver-specificity of Myrcludex B, while proving the role NTCP plays in HBV hepatotropism. 20 
Conclusion
Treating CHB in children/adolescents often represents a dilemma for pediatricians. Spontaneous natural HBe seroconversion has been shown to occur in the majority of cases by the end of adolescence, with the benefits of inhibiting viral replication under nucleotide/nucleoside analogs only proven in specific subgroups.
The recommendations outlined by ESPGHAN and the National Institute for Health and Care Excellence are available to guide practitioners in their decision-making process through the different steps of CHB evolution in the pediatric population. Moreover, similar guidelines have been published for the USA, 21 and further recommendations along with an overview of current therapeutic strategies have recently been issued by the World Health Organization 22 and Clemente et al., 23 respectively, providing precious help to practitioners.
Fundamental research also allows for a better understanding of both the HBV disease and life-cycle, resulting in innovative drugs targeting specific key proteins. This opens up the possibility of new perspectives for treating such a vulnerable population in an appropriate and effective way.
